期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 16, 期 39, 页码 5009-5010出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v16.i39.5009
关键词
Tadalafil; Portal hypertension; Cirrhosis; Ascites; Phosphodiesterase-5 inhibition
A recent report introduced the phosphodiesterase-5 inhibition by vardenafil as a novel treatment of portal hypertension in patients with cirrhosis. In the herein presented letter to the editor, the administration of tadalafil did not influence portal haemodynamics but impaired systemic haemodynamics in patients with cirrhosis. Our observations concur with the results of a report in a previous issue of World Journal of Gastroenterology (October 2008). Moreover, tadalafil adversely affected renal function in patients with decompensated liver disease. (C) 2010 Baishideng. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据